Wockhardt Limited (BOM: 532300)

Market Cap	236.29B
Revenue (ttm)	29.81B
Net Income (ttm)	-2.88B
Shares Out	n/a
EPS (ttm)	-19.64
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	41,164
Open	n/a
Previous Close	n/a
Day's Range	n/a
52-Week Range	402.05 - 1,536.40
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Feb 13, 2025

About Wockhardt

Wockhardt Limited, a pharmaceutical and biotech company, manufactures and trades pharmaceuticals, medicinal, botanical, and chemical products in India, the United States, the United Kingdom, Switzerland, Ireland, Russia, Europe, and internationally. The company develops qualified infectious diseases products comprising WCK5222, which is in phase 3 clinical trial for the treatment of sepsis and hospital/ventilator associated pneumonia; WCK 4282, which is in phase 3 clinical trial for ESBL infections; WCK 6777, which is phase 1 to treat gram nega...

• Industry: Pharmaceutical Preparations
• Founded: 1967
• Employees: 2,386
• Stock Exchange: Bombay Stock Exchange
• Ticker Symbol: 532300

Financial Performance

In 2023, Wockhardt's revenue was 28.30 billion, an increase of 6.51% compared to the previous year's 26.57 billion. Losses were -4.63 billion, -17.17% less than in 2022.